Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ELEDON PHARMACEUTICALS, INC.

(ELDN)
  Report
Delayed Nasdaq  -  03:58:15 2023-01-30 pm EST
3.001 USD   -8.78%
01/09Eledon Pharmaceuticals, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/09Eledon Pharmaceuticals Provides Business and Pipeline Updates
GL
01/09EGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

11/14/2022 | 05:10pm EST

Eledon Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 10.47 million compared to USD 9.82 million a year ago. Basic loss per share from continuing operations was USD 0.73 compared to USD 0.66 a year ago.
For the nine months, net loss was USD 29.58 million compared to USD 25.7 million a year ago. Basic loss per share from continuing operations was USD 2.07 compared to USD 1.73 a year ago.


ę S&P Capital IQ 2022
All news about ELEDON PHARMACEUTICALS, INC.
01/09Eledon Pharmaceuticals, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
01/09Eledon Pharmaceuticals Provides Business and Pipeline Updates
GL
01/09EGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Pr..
AQ
01/09Eledon Pharmaceuticals Provides Business and Pipeline Updates
AQ
01/09Egenesis and Eledon Pharmaceuticals Announces Collaboration for Use of Tegoprubart in P..
CI
2022C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox..
GL
2022C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox..
AQ
2022ELEDON PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditi..
AQ
2022Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
2022Transcript : Eledon Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 14, 202..
CI
More news
Analyst Recommendations on ELEDON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -40,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,15x
Yield 2022 -
Capitalization 41,3 M 41,3 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 1,65x
Nbr of Employees 12
Free-Float 90,2%
Chart ELEDON PHARMACEUTICALS, INC.
Duration : Period :
Eledon Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 3,00 $
Average target price 19,40 $
Spread / Average Target 546%
EPS Revisions
Managers and Directors
David-Alexandre C. Gros Chief Executive Officer & Director
Steven N. Perrin President, Director & Chief Scientific Officer
Paul Little Chief Financial & Accounting Officer
Keith A. Katkin Chairman
Jeffrey D. Bornstein Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ELEDON PHARMACEUTICALS, INC.44.30%45
VERTEX PHARMACEUTICALS11.31%82 513
REGENERON PHARMACEUTICALS, INC.2.96%79 336
WUXI APPTEC CO., LTD.18.94%42 407
BIONTECH SE-4.37%34 912
BEIGENE, LTD.18.12%27 008